Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(50.0%)
Phase 2
1(25.0%)
Phase 4
1(25.0%)
4Total
Phase 3(2)
Phase 2(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01478737Phase 2Completed

Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy

Role: lead

NCT02274259Phase 4Completed

Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen

Role: lead

NCT01478763Completed

Vitrous Analysis in Proliferative Diabetic Retinopathy

Role: lead

NCT00906685Phase 3Completed

Bevacizumab for Central Retinal Vein Occlusion Study

Role: lead

NCT00599222Phase 3Completed

The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study

Role: lead

All 5 trials loaded